Navigation Links
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Date:7/30/2008

-term benefits to Alzheimer's patients and provide further support for its potential as a promising therapeutic to treat this devastating disease."

Patients originally on placebo for 12 months who were then crossed over to Dimebon in the open-label extension phase stabilized across all key measures tested. Since these patients had declined over the previous 12 months while on placebo, they generally stabilized at a lower level of function than those treated with Dimebon for the full 18 months, suggesting a benefit of earlier treatment.

Dimebon Benefits Both Mild and Moderate Patients in 12-month Subgroup Analyses

New data from subgroup analyses by disease severity of the Dimebon double-blind placebo-controlled trial showed that Dimebon benefited both mild and moderate patients. In both mild and moderate patients, Dimebon treatment resulted in significant benefit on the study's primary endpoint, the Alzheimer's Disease Assessment Scale-cognition subscale, or ADAS-cog. The benefit in the moderate subpopulation was particularly robust, with a 9.7 point drug-placebo difference on the ADAS-cog (p<0.0001) after 12 months of treatment.

The subgroup analyses were presented in a separate poster presentation at ICAD 2008 by Rachelle Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. "A nearly 10-point improvement over placebo in moderate patients on the ADAS-cog, a well-validated cognition scale in Alzheimer's disease, is unquestionably of clinical significance, especially in light of a clinical effect seen on the clinician's assessment of global function," said Dr. Doody. "If the results we saw for both the mild and moderate patients can be replicated, I believe that Dimebon will be an important advance in the treatment of Alzheimer's disease, regardless of stage."

Dimebon's Novel Mechanism of Action

In a podium
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
2. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
3. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
4. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
6. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
7. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
8. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Influenza will affect as many as 200,000 people this year ... as high as 49,000 people.  The main way ... to person in respiratory droplets of coughs and sneezes. ... kills much fewer people each year than the Flu. The ... sweat, saliva, blood and other bodily fluids. The Ebola virus ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... The Society for Biomolecular Sciences, now officially the ... and Screening (SLAS), invites students, graduate students, post-doctoral associates ... Travel Award to be used for the SBS 17th ... FL, USA. Applicants must be the primary ...
... Nov. 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Conference in Phoenix, Arizona on Thursday, November 11, 2010 at ... M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, ... be webcast live through the "Investors" section of Amylin,s corporate ...
Cached Medicine Technology:Applications Now Being Accepted for SBS 17th Annual Conference & Exhibition Academic Travel Awards 2
(Date:10/22/2014)... News) -- The United States is now mandating ... of West Africa land at one of five ... the virus. In a statement released Tuesday, ... percent of air passengers from Guinea, Liberia and ... five airports -- New York City,s Kennedy International ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter , ... young adult men may lead to increased blood pressure, according ... a similar rise in blood pressure for young adult women ... young adult women drank lightly or moderately, their risk of ... "This finding parallels studies in older adult men and ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... report issued today identifies the enormous global impact of preterm birth ... estimated 13 million babies are born preterm each year. Newborn deaths ... under the age of five, a rise from 37 percent in ... each year, and many of these losses are linked to maternal ...
... , ... ... ... ...
... , ... International, Inc. has announced its official launch. , ... Anaheim, CA (Vocus) February 18, 2010 -- After a ... official launch. The pilot ramp-up period was designed to simultaneously test its first product ...
... ... ... ... ...
... ... ... ... ...
... limited to physical function but also extend to neurological function, ... Journals of Gerontology Series A: Biological and Medical Sciences ... a collection of ten articles highlighting new findings related to ... consequences of improved medical management of cardiovascular disease is that ...
Cached Medicine News:Health News:Experts call for acceleration of research and interventions for prematurity and stillbirth 2Health News:Experts call for acceleration of research and interventions for prematurity and stillbirth 3Health News:Experts call for acceleration of research and interventions for prematurity and stillbirth 4Health News:Experts call for acceleration of research and interventions for prematurity and stillbirth 5Health News:GREENGUARD Environmental Institute Revamps Web Site 2Health News:GREENGUARD Environmental Institute Revamps Web Site 3Health News:GREENGUARD Environmental Institute Revamps Web Site 4Health News:GREENGUARD Environmental Institute Revamps Web Site 5Health News:GREENGUARD Environmental Institute Revamps Web Site 6Health News:GREENGUARD Environmental Institute Revamps Web Site 7Health News:National Launch of Jusuru International 2Health News:National Launch of Jusuru International 3Health News:ATR: The Individual Mandate Excise Tax is a Tax 2Health News:ATR: The Individual Mandate Excise Tax is a Tax 3Health News:ATR: The Individual Mandate Excise Tax is a Tax 4Health News:ATR: The Individual Mandate Excise Tax is a Tax 5Health News:Brookdale Announces New Corporate Line of Credit 2Health News:Brookdale Announces New Corporate Line of Credit 3Health News:Brookdale Announces New Corporate Line of Credit 4Health News:Brookdale Announces New Corporate Line of Credit 5Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2
... II system is the Cambridge ... Alternans (MTWA) testing platform which ... cardiac death risk stratification. This ... as it can be configured ...
... incorporate 3 mirrors angled at 76°, 66° and ... chamber as well as central and peripheral fundus ... are accurately angled and spaced 120° apart to ... central portion of the lens also provides direct ...
... provides the highest magnification of ANY gonioscopy lens ... the trabecular meshwork. One 62° mirror presents ... while the central portion of the lens can ... signs of glaucoma and other central retinal maladies. ...
... ultra-clear Volk 3-Mirror optics, incorporating 3 mirrors ... The 3 Mirror is ideal for ... fundus viewing and treatment. The retinal viewing ... in the visualized fundus. The central portion ...
Medicine Products: